Entries by optimus
Weekly round-up: Optimism is in the air after BIO-EUROPE Spring
Sofinnova Partners exceeds target with €165m biotech acceleration fund close, Europe’s largest, with strong Pharma support Sofinnova Partners announced the final close of Sofinnova Biovelocita II. The fund has exceeded its target, successfully raising €165M, with substantial backing from the top global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures. iOnctura strengthens leadership […]
Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
Promising data in the clinical trial with HDP-101 in multiple myeloma, including a complete remission in one patient; study progressing well First approvals for clinical trial with ATAC candidate HDP-102 received; study start soon Financial figures in line with plan with improved operating result and lower cash requirements Payment of USD 20 million from HealthCare […]
Poolbeg Pharma plc – POLB 001 Patent Granted in Korea
Grant further strengthens Poolbeg’s global intellectual property (“IP”) portfolio 20 March 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that the Korean Intellectual Property Office has notified the Company of its official decision to grant Poolbeg’s Republic of Korea Immunomodulator II patent application […]
iOnctura commences randomized Phase II study in metastatic uveal melanoma
First patient dosed in Phase II OCULE-01 study with roginolisib, an allosteric modulator of PI3Kδ The European Medicines Agency (EMA) has granted Orphan Drug Designation for roginolisib for treatment of uveal melanoma – benefits include 10 years market exclusivity in the European Union Geneva, Switzerland and Amsterdam, The Netherlands, 20 March 2025 – iOnctura, a […]
